Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hdt Bio Corp. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 examiners and 3 art units, indicating that each identified action sits in a separate examination channel. This distribution increases the value of a coordinated claim vocabulary, while preserving the need for file-specific responses to different technical and procedural concerns.
VYAS, KEYUR ANILKUMAR is the busiest examiner, with 1 pending matter. The available record assigns the remaining matters to other examiners and art units. Counsel should compare the files for recurring claim issues, but should not assume that the same amendment or argument will receive identical treatment across the separate assignments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| HARTLEY, MICHAEL G | 1 | 38.0% | +74.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612850 | COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN BINDING PROTEINS | VYAS, KEYUR ANILKUMAR | 36d overdue |
| 16964733 | CONJUGATABLE DESMOGLEIN 2 (DSG2) BINDING PROTEINS AND USES THEREFOR | HARTLEY, MICHAEL G | 23d overdue |
| 18612893 | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF | HASAN, KHALEDA B | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1637 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18612893 | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18612850 | COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN BINDING PROTEINS | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 36d overdue | Pending | Mar 21, 2024 |
| 16964733 | CONJUGATABLE DESMOGLEIN 2 (DSG2) BINDING PROTEINS AND USES THEREFOR | HARTLEY, MICHAEL G | 1618 | §103 | Final Rejection | 23d overdue | Pending | Jul 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHdt Bio Corp. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Khaleda B Hasan has the most, with 1 of Hdt Bio Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
